In a randomized study, CIMAvax-EGF as a switch maintenance treatment compared to best supportive care alone after first-line platinum-based chemotherapy for metastatic NSCLC demonstrated superior overall survival, particularly in patients with high baseline circulating serum EGF levels (11). Here, EGF is linked to non-small cell lung carcinoma.